GlassScriptPhysician profile
Ashish K Masih
NPI 1093857971
$157,779.09
in general payments reported to CMS, 2019-2025
49 companies · $7,903 in 2025
The $7,903 reported for 2025 was more than what 88% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,178 · 2020: $33K · 2021: $37K · 2022: $50K · 2023: $14K · 2024: $14K · 2025: $7,903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Food and Beverage: $5,877 · Travel and Lodging: $2,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,637.50 |
| Food and Beverage | $5,877.29 |
| Travel and Lodging | $2,244.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $110,967.71 | 2021-2025 | |
| Allergan, INC. | $40,309.17 | 2019-2021 | |
| Ucb, INC. | $664.80 | 2019-2025 | Nayzilam, Briviact, Fintepla |
| Lundbeck LLC | $407.21 | 2019-2025 | Vyepti |
| Pfizer INC. | $406.58 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $367.16 | 2019-2025 | Ultomiris |
| Neurocrine Biosciences, INC. | $351.83 | 2023-2025 | Ingrezza, Ongentys |
| Supernus Pharmaceuticals, INC. | $323.20 | 2019-2023 | |
| Argenx US, INC. | $289.77 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Teva Pharmaceuticals USA, INC. | $280.06 | 2019-2025 | Ajovy, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $270.28 | 2019-2025 | |
| Livanova USA, INC. | $227.83 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Acadia Pharmaceuticals INC | $218.40 | 2024-2025 | Nuplazid, Daybue |
| Merz Pharmaceuticals, LLC | $200.66 | 2022-2025 | Xeomin, Inbrija |
| Amgen INC. | $195.67 | 2019-2021 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $194.88 | 2025 | Symbravo |
| Lilly USA, LLC | $163.22 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Ge Healthcare | $161.62 | 2022-2025 | |
| Eisai INC. | $158.94 | 2023-2025 | |
| Mdd US Operations, LLC | $146.16 | 2019-2022 | |
| Genentech USA, INC. | $140.24 | 2023-2025 | Ocrevus Zunovo, Ocrevus |
| Sk Life Science, INC. | $117.24 | 2024-2025 | |
| Catalyst Pharmaceuticals, INC. | $107.67 | 2023-2024 | Fycompa |
| Octapharma USA, INC. | $89.93 | 2023 | Panzyga |
| Amneal Pharmaceuticals LLC | $87.25 | 2023-2025 | Crexont, Ongentys 50mg Capsules 30, Rytary |
| Neurelis, INC. | $86.82 | 2024-2025 | Valtoco |
| Genzyme Corporation | $86.48 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $72.41 | 2023-2024 | Onpattro |
| Acorda Therapeutics, INC | $69.03 | 2019 | |
| Jazz Pharmaceuticals INC. | $66.41 | 2025 | |
| Sunovion Pharmaceuticals INC. | $61.49 | 2019-2022 | |
| Biogen, INC. | $60.08 | 2019-2024 | Skyclarys |
| Averitas Pharma INC. | $51.64 | 2025 | Qutenza |
| Csl Behring | $48.06 | 2025 | Hizentra, Privigen |
| Tg Therapeutics, INC. | $41.29 | 2025 | |
| Celgene Corporation | $34.16 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $33.52 | 2025 | Dysport |
| Corium, LLC | $27.73 | 2023 | Adlarity |
| Ani Pharmaceuticals, INC. | $25.05 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $22.81 | 2025 | Rexulti |
| Kyowa Kirin, INC. | $20.73 | 2023 | Nourianz |
| Ns Pharma, INC. | $20.29 | 2024 | Viltepso |
| Mallinckrodt Enterprises LLC | $19.89 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.98 | 2025 | Rexulti |
| Emd Serono, INC. | $17.93 | 2019 | |
| Impel Pharmaceuticals INC. | $15.83 | 2023 | Trudhesa |
| Janssen Pharmaceuticals, INC | $15.03 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.21 | 2021 | |
| Sumitomo Pharma America, INC. | $4.74 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashish Masih listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.